Targeting BRCA2 deficiency with GSK3 inhibitors

Targeting BRCA2 deficiency with GSK3 inhibitors

<p>BRCA1 and BRCA2 tumour suppressors are essential for homologous recombination-mediated double-strand break repair and replication fork protection. Therefore, BRCA1 and BRCA2 are essential for cell viability. Deactivating mutations in one of these genes lead to genome instability and are ass...

Fuld beskrivelse

Bibliografiske detaljer
Hovedforfatter:	Zonderland, G
Andre forfattere:	Tarsounas, M
Format:	Thesis
Udgivet:	2017

Lignende værker

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
af: Tacconi, E, et al.
Udgivet: (2019)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
af: Eliana MC Tacconi, et al.
Udgivet: (2019-05-01)

Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds
af: Zimmer, J, et al.
Udgivet: (2016)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
af: Ashwin Ragupathi, et al.
Udgivet: (2023-03-01)

Novel approaches for targeting BRCA2-deficient tumour cells
af: Tacconi, E
Udgivet: (2015)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
af: Ilirjana Bajrami, et al.
Udgivet: (2021-11-01)

GSK-3 inhibitors induce chromosome instability
af: Staples Oliver D, et al.
Udgivet: (2007-08-01)

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells
af: Rebecca A. Dagg, et al.
Udgivet: (2021-08-01)

Lithium and Therapeutic Targeting of GSK-3
af: Melinda E. Snitow, et al.
Udgivet: (2021-01-01)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
af: Giuseppa Augello, et al.
Udgivet: (2020-06-01)

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors
af: Xuexia Xie, et al.
Udgivet: (2024-10-01)

Machine Learning for Discovery of GSK3β Inhibitors
af: Patricia A. Vignaux, et al.
Udgivet: (2020-10-01)

GSK-3 inhibitors: preclinical and clinical focus on CNS
af: Hagit eEldar-Finkelman, et al.
Udgivet: (2011-10-01)

GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
af: Sorin Hostiuc, et al.
Udgivet: (2019-01-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
af: Shicheng Yang, et al.
Udgivet: (2023-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
af: Tingting Du, et al.
Udgivet: (2022-07-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
af: Karolina N. Dziadkowiec, et al.
Udgivet: (2017-02-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
af: Tacconi, E, et al.
Udgivet: (2017)

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells
af: Qianye Yang, et al.
Udgivet: (2021-04-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
af: Zatreanu, D, et al.
Udgivet: (2021)

Targeting of CRMP-2 to the primary cilium is modulated by GSK-3β.
af: Young Ou, et al.
Udgivet: (2012-01-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
af: Eliana MC Tacconi, et al.
Udgivet: (2017-07-01)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
af: Julieta Martino, et al.
Udgivet: (2023-04-01)

The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of β-catenin, a GSK3 substrate, in human glioblastoma cells
af: Ata ur Rahman Mohammed Abdul, et al.
Udgivet: (2018-01-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
af: Diana Zatreanu, et al.
Udgivet: (2021-06-01)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
af: Yosuke Akiba, et al.
Udgivet: (2016-03-01)

Novel reporter alleles of GSK-3α and GSK-3β.
af: William B Barrell, et al.
Udgivet: (2012-01-01)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
af: Julieta Martino, et al.
Udgivet: (2023-11-01)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
af: Przemysław Duda, et al.
Udgivet: (2020-04-01)

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
af: Salar Farokhi Boroujeni, et al.
Udgivet: (2023-11-01)

GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.
af: Sin-Aye Park, et al.
Udgivet: (2016-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
af: Robert A. Smith, et al.
Udgivet: (2023-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232.
af: Robert A Smith, et al.
Udgivet: (2023-01-01)

Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
af: Martinez, Ana, 1961-, et al.
Udgivet: (2006)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
af: Xia Ding, et al.
Udgivet: (2016-08-01)

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
af: Geoffrey I Shapiro, et al.
Udgivet: (2023-11-01)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
af: Melissa S Cline, et al.
Udgivet: (2018-12-01)

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
af: Suggala Ramya Shri, et al.
Udgivet: (2023-11-01)

Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches
af: Rosa Buonfiglio, et al.
Udgivet: (2020-05-01)

Computational study of some cancer drugs as potent inhibitors of GSK3β
af: David Ebuka Arthur, et al.
Udgivet: (2020-11-01)